Application of Lipikar Baume AP+M at least twice daily for 4 weeks on one of the two armsaccording to a randomization scheme The purpose of this study is to observe the skinbarrier function, transepidermal water loss and microbial changes in study participantswith actinic field damage of both arms.It's a randomized, evaluator blinded, intra-individual controlled study conducted in onecenter in Germany, in adult subjects having AK (grade I to III) lesions on the forearmsand back of hands and meeting specific inclusion/exclusion criteria.A total of 20 subjects will be enrolled.The study design consists in 4-week evaluation period, with 2 visits per subject:Screening/Baseline (Day 0, Day 28 (end of Lipikar Baume AP+M application)).
Not Provided
Other: Lipikar Baume AP+M
• Lipikar Baume AP+M Application of Lipikar Baume AP+M at least twice daily for 4 weeks
on one of the two arms according to a randomization scheme
Inclusion Criteria:
- Male, female, diverse persons (> 18yo) who are capable of giving consent
- Female patients are eligible if the subject is not a woman of childbearing potential
(WOCBP) or if she is postmenopausal (cessation of menstruation >12 months) or
surgically sterile (bilateral tubal ligation, bilateral oophorectomy, total
hysterectomy)
- Signed informed consent
- Diagnosis of at least 4 actinic keratoses of the the forearm and/or back of the hand
(each arm)
- Olsen grade I, II and/or III
- Subjects with similar severity and number of AKs on each side symmetrically
- The study participant is in good general condition for his or her age and does not
currently have any active diseases that, in the opinion of the investigator, justify
exclusion from the study
Exclusion Criteria:
- Known or documented intolerance to any of the ingredients of Lipikar Baume AP+M
- Any planned AK treatment during the study
- Treatment of actinic keratoses in the application area within the past 3 Months
(e.g. photodynamic therapy, topical 5-FU, diclofenac, imiquimod, cryotherapy etc.)
- Suspected invasive squamous cell cancer in the application area
- Chronic wounds, erosions, pre-existing infected skin or inflammation which, in the
opinion of the investigator, are in need of treatment other than the study product
- Suspected non-compliance
- Current or within the last 8 weeks given systemic cancer medication or systemic
treatment with 5-Fluorouracil
- Any systemic immunosuppressant given within the 8 weeks prior to the study (e.g.
systemic prednisolone, azathioprine etc.)
- Locally applied retinoids, steroids, or other prescribed externals in the 4 weeks
prior to the start of the study that, in the opinion of the study physician,
necessitate exclusion
- Products containing glycolic or alpha-hydroxy acids applied locally in the
application area in the last 4 weeks
- Participation in another clinical trial
- Participation in a clinical study within the last 30 days
- Family members or colleagues of the investigator
- Participant is in a position or has a relationship with the investigator that
presents a potential conflict of interest
CentroDerm GmbH
Wuppertal, NRW, Germany
Investigator: Thomas Dirschka, Prof. Dr. med.
Contact: 0049 (0) 202 629337 57
studien@centroderm.de
Thomas Dirschka, Prof. Dr.
+49 (0) 202 - 62 933 70
info@centroderm.de
Thomas Dirschka, Prof. Dr., Principal Investigator
CentroDerm GmbH